Shoppers for clear medical advice are finding mixed messages: clinicians across oncology, genetics and surgery aren’t always on the same page about breast cancer risk assessment for people seeking gender-affirming top surgery, and that matters because most chest masculinisation procedures leave behind breast tissue.

Essential takeaways

  • Unclear responsibility: Many clinicians reported not knowing whose job it is to screen or counsel patients about breast cancer risk before top surgery.
  • Residual tissue matters: Most gender-affirming chest surgeries leave tissue behind for aesthetic reasons, so cancer risk is reduced but not eliminated.
  • Conflicting guidance: Providers struggle with competing guidelines from different medical associations, which leads to inconsistent care.
  • Younger patients complicate things: People seeking top surgery often are under standard screening ages, so lifetime and hereditary risk conversations can be tricky.
  • Fixes recommended: Researchers call for defined institutional ownership, unified evidence-based guidelines, and routine post-op surveillance of residual breast/chest tissue.

Why surgeons, oncologists and geneticists are passing the buck

Interviews with clinicians experienced in gender-affirming care revealed a surprising pattern: many professionals defer the question of who should assess breast cancer risk. One genetic counsellor described defaulting to specialty teams, while an oncologist said they “hope” the surgeon handles screening. That passing of responsibility creates a real risk that nobody raises the conversation at all, leaving patients unaware that residual tissue still carries some cancer risk. For patients that can feel unnerving , you’d expect a clear plan, not a game of hot potato.

Context matters: gender-affirming chest masculinisation is often performed when people are younger than typical breast-screening ages, and aesthetic priorities mean surgeons may deliberately leave tissue. So the duty to discuss lifetime risk sits at the intersection of specialties, and not everyone wants to claim it. The researchers suggest institutions should make ownership explicit so a patient doesn’t slip through the cracks.

Residual chest tissue: what it means for cancer risk

Most top surgeries aren’t total mastectomies; they’re designed to create a masculine chest while preserving some tissue for shape. That’s great for aesthetics, but it means cancer risk isn’t eliminated. Clinicians in the study emphasised the need to weigh prevention against the harms of repeated operations , “we’d rather you not have multiple surgeries,” one counsellor said , so the conversation is nuanced. Patients should know the procedure type and how much tissue remains, because that affects follow-up plans.

Practically, ask your surgical team whether the operation is a subcutaneous or total removal, what visible scarring and contour changes imply for residual tissue, and whether they’ll recommend periodic imaging or clinical exams afterwards. It helps to get this on record before consenting to surgery, especially if you have a family history of breast cancer.

Conflicting guidelines are muddying decisions

Providers told researchers they face competing recommendations from different medical bodies, which makes consistent counsel difficult. Without a single, unified guideline that addresses transgender and gender-diverse (TGD) patients explicitly, clinicians often rely on local champions , individuals who push for best practice within an institution , to fill the gap. That patchwork approach means patients in different cities or clinics can receive very different advice.

Industry observers say unified, evidence-based guidance would reduce variation and give clinicians a clear path: who performs risk assessment, when genetic testing should be considered, and how surveillance works post-op. Until then, anyone seeking top surgery should proactively ask their care team which guideline they follow and whether genetics or oncology input will be offered.

Young age at surgery: hereditary risk and timing dilemmas

Many transmasc and non-binary people pursue top surgery in their 20s or 30s, often before routine mammography would start. That makes lifetime risk conversations and hereditary testing decisions , for genes such as BRCA1 and BRCA2 , more complicated. Genetic counsellors in the interviews noted cases where younger patients might have a meaningful hereditary risk but are also keen to avoid multiple procedures.

If you’re young and planning surgery, it’s reasonable to request at least a family-history review and discussion about whether germline testing is appropriate. According to clinical studies, identifying high-risk mutations changes management: it could shift surgical choices, prompt earlier surveillance, or influence hormone and reconstruction plans. Those are weighty decisions; insist on a multidisciplinary discussion rather than a single quick sign-off.

What researchers want: clear ownership and routine surveillance

The study’s authors call for urgent, coordinated changes: designate which team owns preoperative risk evaluation, create unified guidelines that include TGD patients, and ensure postop surveillance explicitly evaluates residual breast/chest tissue. They argue these steps are essential to reduce missed diagnoses and make oncology care truly inclusive. It’s a pragmatic blueprint , sensible, if institutions will actually implement it.

For patients and advocates, that means asking for clarity. Request written care pathways, ask whether your clinic has a multidisciplinary meeting that includes genetics and oncology, and check what follow-up imaging or clinical exams are planned. Those small acts of advocacy often move systems faster than waiting for formal policy updates.

It's a small change that can make every consultation a safer one.

Source Reference Map

Story idea inspired by: [1]

Sources by paragraph: